Profile
- Teaching students of medicine, dental medicine, pharmacy, biomedical sciences as well as graduate students at the Graduate School of Cellular and Biomedical Sciences (GCB) of the University of Bern
- 9 research groups; research focus: investigation of epidemiological and pathophysiological processes as well as diagnosis, prognosis, and therapeutic approaches of blood-related disorders, pathophysiological processes that contribute to inflammation and tumor diseases
- Clinical Study Management Unit (currently 19 ongoing studies)/ Biobanking
- Largest clinical cell therapy program in Switzerland
External Partners
Steering committee and Advisory Board of Hereditary TTP Registry (www.ttpregistry.net); University of Oklahoma Health Sciences Center, Norman, OK, US; American Society for Transplantation and Cellular Therapy – Survivorship Special Interest Group, EBMT Chronic Malignancies Working Party (CMWP); DKFZ Heidelberg, Heidelberg, Germany; Hematology, Basel University Hospital, Basel, Switzerland; MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK; University Hospital Zurich and ETH Zurich, Zurich, Switzerland; Swiss MDS Registry and Biobank; Silence Therapeutics Silence Therapeutics GmbH, Berlin, Germany & plc, London, UK; University of Ottawa, Ottawa, Canada; Lowy Cancer Research Centre, UNSW Sidney, NSW, Australia; Swiss Personalized Health Network (SPHN); Foundation MPN Research Switzerland (Co-founder); Swiss Mastocytosis SCNM (Co-founder); Memorial Sloan Kettering Cancer Center, New York, USA; NYU Langone Perlmutter Cancer Center, New York, USA; Ajax Therapeutics, Cambridge, MA, USA
Grants
- SNSF 192635, 189090, 185233, NFP78 4078P0_198255, PCEFP3_181357
- Swiss Cancer Grant (KFS-5158-08-2020), SAKK Grant 33/18
- Bernese Cancer League, Jacques und Gloria Gossweiler Stiftung, Fondazione San Salvatore, Stiftung für krebskranke Kinder (Basel); Foundation for the Fight against Cancer
- 3rd Call for Proposals for Personalized Health and Related Technologies PHRT project #2019-717
- IIR grant (H16-36165) from Baxalta US Inc., Novartis CINC424BCH01R, CSL Behring AG, Alexion,
- Unrestricted grant from Silence Therapeutics, Access to Insight Funding (NovoNordisk)